 |
|
 |
Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Front-line Therapy with Alemtuzumab (Campath®) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia
Results to be posted pending publication
Drug Name
|
Generic Name
|
Therapeutic Area and FDA Approved Indications:
|
Approved U.S. Drug Label
|
Campath®
|
Alemtuzumab
|
B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy
|
Prescribing Info
NOTE: This product is manufactured by Genzyme Corporation and distributed by Bayer Healthcare Pharmaceuticals
|
|
 |
 |
 |
 |
Contact Information
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
T:617 252 7500
F:617 252 7600
Contact Us
|
 |
 |
|
 |